An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

Data ReadoutPositive

AI Analysis

Summary

Alkermes' orexin drug demonstrated proof-of-concept in ADHD with results anticipated in 2027, while AbbVie advanced AI drug discovery efforts and the FDA expanded use of Eli Lilly's breast cancer medication.

Outcome Details

Orexin drug showed proof-of-concept in ADHD with readout expected in 2027

Importance:5/10

Sentiment:

0.30

ADHDorexinproof-of-conceptAI drug discoverybreast cancerFDA expansion

Related Companies

$ABBV $LLY

Read the original article

Published by BioPharma Dive on September 22, 2026 2:17 PM

Read Original